Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
|Videos|March 9, 2016
Classes of Antidiabetic Agents Recommended as Second-Line Therapies for Type 2 Diabetics
Susan Cornell, PharmD, CDE, FAPhA, FAADE outlines the classes of antidiabetic agents recommended as a second-line treatment for type 2 diabetics.
Advertisement
Susan Cornell, PharmD, CDE, FAPhA, FAADE outlines the classes of antidiabetic agents recommended as a second-line treatment for type 2 diabetics.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Advertisement
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Advertisement
Advertisement
Trending on Pharmacy Times
1
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
2
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
3
Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?
4
Pharmacists Positioned as Key Educators as Monoclonal Antibodies Emerge as COVID-19 Immunization Option
5